Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
2025
Month
1
2
3
4
5
6
7
8
9
10
11
12
13
2022-09
Boan Biotech’s Broad-Spectrum Neutralizing Antibody BA-CovMab Injection Approved for Clinical Trials in China
08
2022-09
Boan Biotech’s Investigational Anti-CD25 Antibody BA1106 Approved for the First Clinical Trial on Treating Solid Tumors in China
15
2022-07
Boan Biotech Starts Phase III Clinical Trial in China for Dulaglutide Injection (BA5101)
25
2022-02
Boan Biotech's Boyounuo® (Bevacizumab Injection) Approved for Two New Indications: Ovarian Cancer and Cervical Cancer
26
2022-01
First Patient Enrolled in Phase I Clinical Trial for Boan Biotech’s Investigational Anti-Claudin 18.2 Antibody Drug BA1105
14
2021-12
Boan Biotech's Anti-PD-L1/TGF-β Bispecific Antibody BA1201 Approved for Clinical Trials in China
25
2021-11
Boan Biotech Publishes Results of Anti-CD25 Antibody Research in Nature Sub-Journal
24
2021-11
Boan Biotech Reaches Strategic Collaboration Agreement with Merck to Build Its “Digital Factory of the Future”
13
2021-10
Marketing Authorization Application for Boan's Denosumab Injection Accepted in China
04
2021-10
Boan Biotech’s New ADCC-Enhanced Anti-Claudin 18.2 Antibody Drug BA1105 Approved for Clinical Trials in China
4
5
6
7
8
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
